Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499928 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00499928 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 6 participants.
The verdict
NCT00499928, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will examine the biological fate of radioactive SB-751689 administered to healthy males and healthy postmenopausal women. Subjects will receive a single oral dose of radioactive SB-751689. Excreta and blood samples will be taken over the course of 7 days. This study will help determine the major route of elimination of SB-751689 in humans. It will also provide samples (blood, plasma, urine, and stools) for analysis of metabolites, if any.
Interventions
- DRUG SB-751689
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499928
The ClinicalTrials.gov registry entry for NCT00499928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB-751689 is the first listed.
NCT00499928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499928 about?
NCT00499928 is a clinical study titled "A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women". This study will examine the biological fate of radioactive SB-751689 administered to healthy males and healthy postmenopausal women. Subjects will receive a single oral dose of radioactive SB-751689. Excreta and blood samples will be taken over the course of 7 days. This study will help determine th...
What is the current status of trial NCT00499928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00499928?
The interventions under investigation include: SB-751689 (DRUG).
Who is sponsoring clinical trial NCT00499928?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.